Spectrofluorimetric assessment of plasma dipyridamole stability: Sample storage for multicenter clinical trials?

Thrombosis Research

Volumn 123, Issue 1, 2008, Pages 184-186

  Serebruany, Victor ^a   Pokov, Ilya ^a   Hanley, Dan ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BLOOD SAMPLING; BLOOD STORAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED DRUG RELEASE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DYSLIPIDEMIA; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; RACE DIFFERENCE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SPECTROFLUOROMETRY;

AGED; BLOOD SPECIMEN COLLECTION; CLINICAL TRIALS AS TOPIC; DIPYRIDAMOLE; DRUG STABILITY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC;

EID: 54049134393     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.07.002     Document Type: Letter

References (9)

1. Fitzgerald G.A. Drug therapy: Dipyridamole. N Engl J Med 316 (1987) 1247-1257
2. De Schyver E., Algra, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Stroke in press;39.
3. Steyn J.M. Spectrofluorimetric determination of dipyridamole in serum-a comparison of two methods. J Chromatogr 164 (1979) 487-494
4. Adams R.J., Alberts G., Alberts M.J., et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39 (2008) 1647-1652
5. Gencheva E., Sloan M., Leurgans S., et al. Attrition and non-compliance in secondary stroke prevention trials. Neuroepidemiology 23 (2004) 61-66
6. Pederson A.K. Specific determination o dipyridamole in serum by high-performance liquid chromatography. J Chromatogr 162 (1979) 98-103
7. Ruiz-Medina A., Fernandez-de Cordova M.L., and Molina-Diaz A. A flow-through optosensing device with fluorimetric transduction for rapid and sensitive determination of dipyridamole in pharmaceuticals and human plasma. Eur J Pharm Sci 13 (2001) 385-391
8. Oshrine B.R., Malinin A.I., Pokov A.N., Dragan A., and Serebruany V.L. Changes of pH are critical for accurate fluorometric measurements of dipyridamole levels in biological fluids. Meth Find Exp Clin Pharm 27 (2005) 95-100
9. Mellinger T.J., and Bohorfoush J.G. Pathways and tissue distribution of dipyridamole. Arch Int Pharmacodyn Ther 156 (1965) 380-388